View Post

Updated recommendations for managing hereditary breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Health Day From: medicalxpress.com One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Following presentation of the results from …

View Post

Savvy Cooperative: Patients who were Part of a Clinical Trial During the COVID-19 Pandemic

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Scope: We need patients who were part of a clinical trial during the COVID-19 pandemic Eligibility Criteria: Were part of a clinical trial during covid Proof of diagnosis/participation will be required to participate Geography: USA Details: Video interview with Savvy that Savvy will edit down into a highlight reel to be used in a pharmaceutical company’s internal meeting as well …

View Post

Positive Topline Survival Data Observed in Phase 3 Trial of SYD985 for HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer. Positive topline results were observed in the phase 3 TULIP study (NCT03262935), which investigated the safety and efficacy of [vic-]trastuzumab duocarmazine (SYD985) compared with physician’s choice of chemotherapy in patients with pretreated …

View Post

FDA Approves Dose-Escalation Label Update for Neratinib in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com THe FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent in patients with HER2-positive breast cancer, as examined in the phase 2 CONTROL trial, and the new 133-count commercial Nerlynx SKU. The FDA has approved a labeling supplement to the US prescribing information …

View Post

City of Hope researchers ID how most common breast cancer becomes resistant to treatment

In Clinical Studies News by Barbara Jacoby

Source: City of Hope From: eurekalert.org Understanding how tumors in patients with early-stage estrogen receptor positive breast cancer evolve to resist certain combination therapies can aid in the design of optimal drug strategies for people whose cancer potentially could be cured City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage …

View Post

Agendia test spots ultralow breast cancer recurrence risks, flagging women who could skip chemo

In Clinical Studies News by Barbara Jacoby

By: Conor Hale From: fiercebiotech.com Breast cancer test maker Agendia has delivered new data showing its MammaPrint genomic diagnostic can help identify patients at an ultralow risk of recurrence, including some who are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans …

View Post

Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society …

View Post

Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence. Olaparib (Lynparza) demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone …

View Post

Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Cantargia AB From: prnewswire.com Cantargia AB today announced signing a Letter of Intent with the Spanish Breast Cancer Group (GEICAM) to perform a new clinical trial investigating the antibody nadunolimab (CAN04) in combination with carboplatin/gemcitabine for the treatment of patients with advanced triple negative breast cancer (TNBC). The trial will investigate the safety and efficacy of the combination in …

View Post

New research points to potential for single breast cancer radiotherapy shot

In Clinical Studies News by Barbara Jacoby

By: Jack Power, Mark Hilliard From: irishtimes.com New research which suggests a single shot of radiotherapy may be as effective as current treatment for certain types of breast cancers, has been described as promising by the Irish Cancer Society. The University College London (UCL) study, published on Friday, suggests a new treatment may avoid the need for a long course …